Edition:
United Kingdom

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

195.26USD
4:10pm BST
Change (% chg)

$1.18 (+0.61%)
Prev Close
$194.08
Open
$194.04
Day's High
$195.81
Day's Low
$194.04
Volume
169,882
Avg. Vol
1,160,984
52-wk High
$211.89
52-wk Low
$166.30

Latest Key Developments (Source: Significant Developments)

Amgen Announces Phase 3 Candor Study Combining Kyprolis And Darzalex Meets Primary Endpoint Of Progression-Free Survival
Friday, 13 Sep 2019 

Sept 13 (Reuters) - Amgen Inc ::AMGEN ANNOUNCES PHASE 3 CANDOR STUDY COMBINING KYPROLIS® (CARFILZOMIB) AND DARZALEX® (DARATUMUMAB) MEETS PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL.AMGEN INC - THERE WAS A HIGHER FREQUENCY OF ADVERSE EVENTS REPORTED IN KDD, A THREE-AGENT REGIMEN, THAN IN KD, A TWO-AGENT REGIMEN.AMGEN - REGIMEN RESULTED IN A 37% REDUCTION IN RISK OF PROGRESSION OR DEATH IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA TREATED WITH KDD.  Full Article

Amgen Highlights New Data From Kyprolis (Carfilzomib) And Oncology Pipeline At IMW 2019
Thursday, 12 Sep 2019 

Sept 12 (Reuters) - Amgen Inc ::AMGEN HIGHLIGHTS NEW DATA FROM KYPROLIS® (CARFILZOMIB) AND ONCOLOGY PIPELINE AT IMW 2019.AMGEN INC - DATA PRESENTED FROM ANTI-BCMA BITE® AND MCL-1 PROGRAMS.AMGEN INC - A PHASE 1 DOSE ESCALATION STUDY OF AMG 701 IS UNDERWAY WITH DATA EXPECTED FOR PRESENTATION IN 2020..AMGEN INC - PHASE 1 DOSE ESCALATION CLINICAL TRIAL FOR AMG 397 (NCT03465540 ) IS ON A CLINICAL HOLD TO EVALUATE A SAFETY SIGNAL FOR CARDIAC TOXICITY.AMGEN INC - AMG 176 PHASE 1 TRIAL (NCT02675452 ) HAS BEEN PLACED ON A VOLUNTARY HOLD FOR NEW ENROLLMENT..AMGEN INC - EXPLORING INTERMITTENT DOSING OPTIONS WITH AMG 420 THAT COULD BE EVALUATED FOLLOWING PHASE 1B STUDY..  Full Article

Amgen sees SG&A, R&D expenses up in 2020 after Otezla deal
Monday, 26 Aug 2019 

Aug 26 (Reuters) - Amgen ::EXEC SEES 2020 NON-GAAP SG&A EXPENSES UP $600-700 MILLION DUE TO ONGOING COST OF OTEZLA-CONF. CALL.EXEC SEES 2020 NON-GAAP RESEARCH AND DEVELOPMENT OPERATING EXPENSES UP $500 MILLION -CONF. CALL.EXEC SEES 2020 SHARE REPURCHASES CONSISTENT WITH 2015-2018 REPURCHASES, EXCLUDING 2018 TENDER-CONF. CALL.  Full Article

Amgen To Acquire Otezla For $13.4 Bln
Monday, 26 Aug 2019 

Aug 26 (Reuters) - Amgen Inc ::AMGEN TO ACQUIRE OTEZLA® FOR $13.4 BILLION IN CASH, OR APPROXIMATELY $11.2 BILLION NET OF ANTICIPATED FUTURE CASH TAX BENEFITS.AMGEN INC - AMGEN WILL FINANCE TRANSACTION WITH CURRENT BALANCE SHEET CASH AND EXPECTS TO RETAIN ITS INVESTMENT GRADE CREDIT RATING.AMGEN INC - BELIEVES ACQUISITION OF OTEZLA TO BE IMMEDIATELY NON-GAAP EPS ACCRETIVE.AMGEN INC - AMGEN'S CAPITAL ALLOCATION PRIORITIES WILL REMAIN UNCHANGED.AMGEN INC - DEAL FOR ABOUT $11.2 BILLION, NET OF PRESENT VALUE OF $2.2 BILLION IN ANTICIPATED FUTURE CASH TAX BENEFITS.AMGEN INC - EXPECTS AT LEAST LOW DOUBLE-DIGIT OTEZLA SALES GROWTH, ON AVERAGE, OVER NEXT FIVE YEARS.  Full Article

Bristol-Myers Squibb Announces Agreement Between Celgene And Amgen To Divest Otezla For $13.4 Billion
Monday, 26 Aug 2019 

Aug 26 (Reuters) - Bristol-Myers Squibb Co ::PRESS RELEASE - BRISTOL-MYERS SQUIBB ANNOUNCES AGREEMENT BETWEEN CELGENE AND AMGEN TO DIVEST OTEZLA FOR $13.4 BILLION.BRISTOL-MYERS SQUIBB ANNOUNCES AGREEMENT BETWEEN CELGENE AND AMGEN TO DIVEST OTEZLA® FOR $13.4 BILLION.BRISTOL-MYERS SQUIBB CO - BRISTOL-MYERS SQUIBB ANNOUNCES AGREEMENT BETWEEN CELGENE AND AMGEN TO DIVEST OTEZLA® FOR $13.4 BILLION.BRISTOL-MYERS SQUIBB CO - AGREEMENT CONTINGENT ON FTC CONSENT DECREE AND CLOSING OF PENDING BRISTOL-MYERS SQUIBB-CELGENE MERGER.BRISTOL-MYERS SQUIBB CO - AGREEMENT CONTINGENT ON FTC CONSENT DECREE AND CLOSING OF PENDING BRISTOL-MYERS SQUIBB-CELGENE MERGER.BRISTOL-MYERS SQUIBB CO - PENDING BRISTOL-MYERS SQUIBB-CELGENE MERGER EXPECTED TO CLOSE BY END OF 2019.BRISTOL-MYERS SQUIBB CO - AGREEMENT INCLUDES TRANSFER OF CELGENE EMPLOYEES PRIMARILY DEDICATED TO OTEZLA.BRISTOL-MYERS SQUIBB CO - INCREASING ITS PREVIOUSLY PLANNED $5 BILLION ACCELERATED SHARE REPURCHASE TO $7 BILLION.BRISTOL-MYERS SQUIBB CO - BRISTOL-MYERS SQUIBB PLANS TO PRIORITIZE USE OF PROCEEDS FROM OTEZLA DIVESTITURE FOR DEBT REDUCTION.BRISTOL-MYERS SQUIBB CO - NOW EXPECTS PENDING MERGER WITH CELGENE TO CLOSE BY END OF 2019..BRISTOL-MYERS SQUIBB CO - AMGEN WOULD ACQUIRE GLOBAL RIGHTS TO OTEZLA (APREMILAST) FOR $13.4 BILLION IN CASH.BRISTOL-MYERS SQUIBB CO - PLANS TO PRIORITIZE USE OF PROCEEDS FROM OTEZLA DIVESTITURE FOR DEBT REDUCTION.  Full Article

Sandoz Will Appeal District Court Of New Jersey Ruling In Biosimilar Erelzi U.S. Patent Case
Friday, 9 Aug 2019 

Aug 9 (Reuters) - Novartis AG::SANDOZ WILL APPEAL DISTRICT COURT OF NEW JERSEY RULING IN BIOSIMILAR ERELZI® (ETANERCEPT-SZZS) US PATENT CASE.SANDOZ TO APPEAL COURT RULING TO UNITED STATES COURT OF APPEALS FOR FEDERAL CIRCUIT.FRIDAY RULING PREVENTS LAUNCH OF IMPORTANT, AFFORDABLE TREATMENT OPTION FOR US PATIENTS AFFECTED BY CHRONIC AUTOIMMUNE AND INFLAMMATORY DISEASES.SANDOZ REMAINS COMMITTED TO PROVIDING ERELZ AS SOON AS POSSIBLE.US DISTRICT COURT OF NEW JERSEY RULED AGAINST SANDOZ IN PATENT LITIGATION CONCERNING SANDOZ BIOSIMILAR, ERELZI FOR REFERENCE MEDICINE ENBREL.SANDOZ WILL APPEAL RULING TO US COURT OF APPEALS FOR FEDERAL CIRCUIT, AND PARTIES HAVE AGREED TO AN EXPEDITED APPEAL..  Full Article

Amgen Reports Qtrly GAAP Earnings Per Share of $3.57
Tuesday, 30 Jul 2019 

July 30 (Reuters) - Amgen Inc ::AMGEN - QTRLY TOTAL REVENUES $5.87 BILLION VERSUS $6.06 BILLION.AMGEN - QTRLY GAAP EARNINGS PER SHARE $3.57; QTRLY NON-GAAP EARNINGS PER SHARE $3.97.Q2 EARNINGS PER SHARE VIEW $3.59, REVENUE VIEW $5.68 BILLION -- REFINITIV IBES DATA.AMGEN - SEES 2019 TOTAL REVENUES $22.4 BILLION TO $22.9 BILLION.AMGEN - QTRLY TOTAL PRODUCT SALES DECREASED 2% GLOBALLY.AMGEN - SEES 2019 GAAP EARNINGS PER SHARE $12.10 TO $12.71.AMGEN - SEES 2019 NON-GAAP EARNINGS PER SHARE $13.75 TO $14.30.FY2019 EARNINGS PER SHARE VIEW $13.97, REVENUE VIEW $22.59 BILLION -- REFINITIV IBES DATA.AMGEN - SEES 2019 CAPITAL EXPENDITURES TO BE ABOUT $700 MILLION.  Full Article

Coherus BioSciences Says Reports Victory in Pegfilgrastim Patent Dispute
Tuesday, 30 Jul 2019 

July 29 (Reuters) - Coherus Biosciences Inc ::US COURT OF APPEALS FOR FEDERAL CIRCUIT AFFIRMS DECISION OF A US DISTRICT COURT THAT CO'S UDENYCA DOES NOT INFRINGE AMGEN'S ASSERTED PATENT.FEDERAL CIRCUIT'S PRECEDENTIAL OPINION AFFIRMED DISTRICT COURT'S JUDGMENT IN COHERUS' FAVOR.  Full Article

Nuevolution Says Board Has Resolved To Apply For Delisting From Nasdaq Stockholm
Thursday, 11 Jul 2019 

July 11 (Reuters) - Nuevolution AB (publ) ::NUEVOLUTION APPLIES FOR DELISTING.AT REQUEST OF AMGEN, BOARD HAS RESOLVED TO APPLY FOR DELISTING OF NUEVOLUTION'S SHARES FROM NASDAQ STOCKHOLM.  Full Article

Amgen Comments On Pcsk9 Patent Litigation In Germany
Thursday, 11 Jul 2019 

July 11 (Reuters) - Amgen Inc ::AMGEN INC. - AMGEN COMMENTS ON PCSK9 PATENT LITIGATION IN GERMANY.AMGEN SAYS "PLANS TO ENFORCE THE COURT’S DECISION AGAINST PRALUENT IN GERMANY".AMGEN - DÜSSELDORF REGIONAL COURT RULED IN FAVOR OF AMGEN CONFIRMING THAT SANOFI-AVENTIS’ PRALUENT® (ALIROCUMAB) INFRINGES AN AMGEN PATENT.AMGEN INC - AT THIS TIME NOT SEEKING REMOVAL OF EXISTING PRALUENT SUPPLIES AVAILABLE AT HOSPITALS AND PHARMACIES.  Full Article

UPDATE 2-Biogen scraps two late-stage trials for Alzheimer's treatment

Sept 13 Biogen Inc and Eisai Co Ltd are abandoning two late-stage trials for their Alzheimer's treatment in a widely anticipated move that comes months after the companies scrapped trials of another drug for the memory-robbing disease.